Friday, August 25, 2023
Paragonix Technologies, a leader in the field of organ transplant solutions, has received official clearance from the US Food and Drug Administration (FDA) for its advanced donor lung preservation system called BAROguard™. This innovative BAROguard™ System combines Paragonix's hypothermic preservation technology with automated airway pressure control, ensuring optimal temperature and inflation pressure for donor lungs during transport from donor to recipient.
This integration of advanced technologies demonstrates Paragonix Technologies' commitment to elevating standards in transplant medicine. Traditionally, donor lungs are transported in an inflated state from donor to recipient.
However, existing techniques struggle to maintain lung inflation pressures within the recommended range. This is crucial, as most donor lung transport occurs by aircraft, exposing lungs to changing ambient pressures and increasing the risk of pulmonary barotrauma.
The BAROguard Donor Lung Preservation System addresses these challenges through an automated and user-friendly pressure management system. Manual lung inflation during donation varies, but maintaining consistent airway pressure can optimize preservation, especially for extended organ recovery periods or distances. The BAROguard system provides automated control over airway pressures and temperature, with real-time reporting to the transplant team.
FDA clearance for BAROguard represents a significant advancement for transplant teams, offering state-of-the-art technology to improve organ transplantation outcomes. This innovation has the potential to enhance success rates and the overall effectiveness of lung transplants, bringing hope to individuals awaiting life-saving procedures.
Source: businesswire.com
